<DOC>
	<DOCNO>NCT01412736</DOCNO>
	<brief_summary>This double-blind , placebo-controlled dose-ranging study KHK4563 evaluate effect multiple-dose subcutaneous administration KHK4563 annual asthma exacerbation rate adult subject uncontrolled , suspect eosinophilic asthma .</brief_summary>
	<brief_title>A Phase IIa Study KHK4563</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<criteria>1 . Age 20 75 year time Week −3 visit . 2 . Written inform consent obtain subject prior performing protocolrelated procedure , include screen evaluation . 3 . Physician prescribed daily use mediumdose highdose ICS plus LABA combination sequential dose either mediumdose highdose ICS/LABA least 12 month prior Week −3 visit . Dose must stable least 30 day prior Week −3 visit . 4 . At least 2 , 6 , document asthma exacerbation 12 month prior Week −3 visit require use systemic corticosteroid burst . Exclusion Criteria 1 . Any condition ( eg , eosinophilic low respiratory disease asthma , ChurgStrauss syndrome , hypereosinophilic syndrome , eosinophilic bronchitis , eosinophilic pneumonia , chronic obstructive pulmonary disease ( COPD ) , bronchiectasis cystic fibrosis ( CF ) ) , opinion investigator Medical Expert , would interfere evaluation investigational product interpretation subject safety study result . 2 . Any clinically relevant abnormal finding physical examination , vital sign , hematology , clinical chemistry , urinalysis screening period , opinion investigator , may put subject risk his/her participation study , may influence result study , subject 's ability participate study . 3 . Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior Week −3 visit screen period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>